Levrett Share Discussion Threads

[maytrees] 19/8/2016 09:21

Slowly but surely N wards again today after weeks of little share price action.

[maytrees] 12/7/2016 14:57

SP nicely up today.

So far so good...

[maytrees] 07/7/2016 10:01

More 250,000 trades - possible something afoot?

[maytrees] 07/7/2016 09:53

Ditto the above today except that the apparent buy share price just now for the 250,000 was 1.73p.
No news yet though

[maytrees] 23/6/2016 16:20

Presumably that 250,000 trade at 1.75 is a buy as dummy sell share price is 1.52p?

[maytrees] 18/5/2016 13:59

Doesn't take much to increase share price or at least offer sp; one small buy and share price goes up.

Whether any more progress has been made in respect of the following part of the Co's half yearly report has yet to be seen:

The recent announcements with regards to Immuno-Oncology advances highlights one example of how the Biotechnology sector in the UK continues to evolve and develop. There are a number of significant opportunities that would make suitable investment targets for Levrett, which was formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector.



The Company has made considerable progress towards identifying such targets focussed on four specific strategic sectors, being; Oncology, Diabetes, Obesity and Mental Health. The Board has reviewed a number of specific targets to date, within the UK, Europe and the United States. Whilst some of these have not met the investment criteria for the Company, the Board continues to review the other opportunities with a view to completing a suitable acquisition.

I hold.

[lloydcohen1962] 11/3/2016 18:31

This really is an interesting one... Was digging around on their website and found the updated corporate presentation - seems they've been busy and reckon deal can't be far off having appointed Whitman Howard in as broker. They've been in the space recently with Faron too. Let me know your thoughts guys. Seems things are are boiling nicely. LC.

[the stigologist] 24/2/2016 07:49

For Immediate Release 17 December 2015

Levrett Plc
("Levrett" or "the Company")

Admission to Trading and First Day of Dealings

Publication of Prospectus

Levrett, a Company formed to acquire a target company (or companies) with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, is pleased to announce that its entire issued ordinary share capital consisting of 95,750,000 Ordinary Shares of £0.001 each (the "Ordinary Shares") will today be admitted to the standard segment of the Official List of the UKLA and to trading on the Main Market for listed securities of the London Stock Exchange (together "Admission"). Dealings are expected to commence at 8:00 a.m. under the TIDM code "LVRT" (ISIN: GB00BYW79Y38).

Levrett is also pleased to announce that copies of the Prospectus in relation to the Admission are available for inspection, subject to applicable securities laws, from the Company's website at www.levrett.com. Defined terms in this announcement shall have the same meanings as in the Prospectus.

Commenting, Pascal Hughes, Chief Executive Officer, said:

"We are very pleased to have successfully concluded the Placing and Admission of Levrett. There are a number of very exciting opportunities in the pharmaceutical and biotechnology sectors which we look forward to exploring further."


Highlights

· Levrett has been formed for the purpose of acquiring a business or businesses operating in the pharmaceutical and biotechnology sector ("the Acquisition").

· The Company will look to acquire a target company with products and technology already at a stage of development that will add value to the target company.

· There remain many categories of serious illness that can and will benefit from technological advances in diagnosis and treatment such as cancer, cardiovascular disease and respiratory disease, together with obesity and diabetes. These areas will be the main, though not the exclusive, focus of the Company.





STATISTICS

Total number of Ordinary Shares issued pre-Admission

50,000,000
Total number of Ordinary Shares issued pursuant to the Placing

45,750,000
Total number of Ordinary Shares in issue on Admission

95,750,000
Placing Price

£0.02
Net Proceeds of the Placing

£915,000
Costs of Admission

£139,897
Market capitalisation of the Company at the Placing Price on Admission

£1.915m